Your session is about to expire
← Back to Search
This trial is testing a new combination of drugs to treat NUT carcinoma and to see if it works to shrink the tumor.
- Neuroendocrine Tumors
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a Location
Who is running the clinical trial?
- You are able to swallow pills and keep them down.You must have a platelet count of at least 125 x 10^9/L for Phase 1, Phase 2, and exploratory groups that do not focus on the lungs or BRD4.If you have received any bone-targeted radionuclide treatment in the past 6 weeks, you are not eligible for this study.You need to have a certain level of white blood cells called neutrophils, which is measured by a blood test.Your hemoglobin level must be at least 9.0 g/dL to participate in the study.You cannot participate in this study if you are currently taking any experimental medications.You have had an allergic reaction in the past to drugs similar to ZEN003694 or other drugs used in this study.Your tumor shows high levels of NUT protein in more than half of the cells, as confirmed by a certified lab test called immunohistochemistry.Your medical tests showed that you have the NUT gene translocation, as determined by fluorescence in situ hybridization (FISH) performed at the Bringham and Women's Hospital (BWH) Center for Advanced Molecular Diagnostics (CAMD).You have a type of disease that has spread to other parts of your body, or it cannot be removed with surgery, or surgery is not a good option for you. If you already had surgery, you can still participate in the study.You are at least 12 years old and weigh at least 40 kilograms. Children younger than 12 years old cannot participate because the medication has not been tested enough in younger children.If you are 16 years or older, your performance status should be equal to or less than 2 (measured through the Eastern Cooperative Oncology Group score), which means you should have a Karnofsky score of 60% or higher. If you are under 16 years old, your performance status should be measured through the Lansky score, and it should be 50% or higher. This criterion applies to Phase 1, Phase 2, and non-thoracic/non-BRD4 exploratory cohort.You must have cancer that can be measured using a specific set of criteria called RECIST version 1.1. If you are participating in phase 1 of the trial, you don't need to have measurable cancer but it should be evaluable in other ways.
- Group 1: Treatment (ZEN-3694, etoposide, cisplatin)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is enrollment still taking place for this research endeavor?
"Indeed, the information posted on clinicaltrials.gov indicates that enrollment for this medical trial is currently ongoing. The study became available to participants in late April 2022 and has been recently updated in November of the same year; it requires 55 volunteers from 2 different locations."
What maladies has BET Bromodomain Inhibitor ZEN-3694 been utilized to combat?
"ZEN-3694, a BET Bromodomain Inhibitor, is usually used to manage advanced cases. Additionally, it has been administered with success in the treatment of merkel cell cancer, neoplasm metastasis and prostate cancerl cancer, neoplasm metastasis and prostate cancer."
Can you inform me of any other experiments involving the BET Bromodomain Inhibitor ZEN-3694?
"At present, 950 trials are being conducted to research the efficacy of BET Bromodomain Inhibitor ZEN-3694. Of those clinical studies, 338 are in their third phase. Beijing remains the epicenter for these experiments; however, 51625 sites have opened up across the world looking into its potential applications."
How many volunteers have taken part in this research study?
"Affirmative. According to information found on clinicaltrials.gov, this trial is actively recruiting and has been since April 29th 2022. The study seeks 55 patients from two different medical centres for enrollment as of November 29th 2022."
Share this study with friends